240 related articles for article (PubMed ID: 10493628)
1. Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion (CHPP).
Park BJ; Alexander HR; Libutti SK; Wu P; Royalty D; Kranda KC; Bartlett DL
Ann Surg Oncol; 1999 Sep; 6(6):582-90. PubMed ID: 10493628
[TBL] [Abstract][Full Text] [Related]
2. Continuous hyperthermic peritoneal perfusion with cisplatin for the treatment of peritoneal mesothelioma.
Ma GY; Bartlett DL; Reed E; Figg WD; Lush RM; Lee KB; Libutti SK; Alexander HR
Cancer J Sci Am; 1997; 3(3):174-9. PubMed ID: 9161783
[TBL] [Abstract][Full Text] [Related]
3. A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis.
Bartlett DL; Buell JF; Libutti SK; Reed E; Lee KB; Figg WD; Venzon DJ; Alexander HR
Cancer; 1998 Sep; 83(6):1251-61. PubMed ID: 9740093
[TBL] [Abstract][Full Text] [Related]
4. Cytoreductive surgery and continuous hyperthermic peritoneal perfusion in patients with mesothelioma and peritoneal carcinomatosis: hemodynamic, metabolic, and anesthetic considerations.
Miao N; Pingpank JF; Alexander HR; Royal R; Steinberg SM; Quezado MM; Beresnev T; Quezado ZM
Ann Surg Oncol; 2009 Feb; 16(2):334-44. PubMed ID: 19050961
[TBL] [Abstract][Full Text] [Related]
5. [Continuous hyperthermic peritoneal perfusion with cisplatin and mitomycin C for peritoneal dissemination in gastric cancer].
Fujimura T; Yonemura Y; Urade M; Sugiyama K; Hasegawa H; Hashimoto T; Miyata R; Matsuda Y; Katayama K; Yamaguchi A
Nihon Gan Chiryo Gakkai Shi; 1989 Jul; 24(7):1415-24. PubMed ID: 2509604
[TBL] [Abstract][Full Text] [Related]
6. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy.
Feldman AL; Libutti SK; Pingpank JF; Bartlett DL; Beresnev TH; Mavroukakis SM; Steinberg SM; Liewehr DJ; Kleiner DE; Alexander HR
J Clin Oncol; 2003 Dec; 21(24):4560-7. PubMed ID: 14673042
[TBL] [Abstract][Full Text] [Related]
7. Multicystic and well-differentiated papillary peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC).
Baratti D; Kusamura S; Nonaka D; Oliva GD; Laterza B; Deraco M
Ann Surg Oncol; 2007 Oct; 14(10):2790-7. PubMed ID: 17661150
[TBL] [Abstract][Full Text] [Related]
8. Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion.
Deraco M; Casali P; Inglese MG; Baratti D; Pennacchioli E; Bertulli R; Kusamura S
J Surg Oncol; 2003 Jul; 83(3):147-53. PubMed ID: 12827682
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic outcomes of continuous hyperthermic peritoneal perfusion against advanced gastric cancer with peritoneal carcinomatosis.
Kunisaki C; Shimada H; Akiyama H; Nomura M; Matsuda G; Otsuka Y; Ono H; Takahashi M
Hepatogastroenterology; 2006; 53(69):473-8. PubMed ID: 16795995
[TBL] [Abstract][Full Text] [Related]
10. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC).
Baratti D; Kusamura S; Cabras AD; Bertulli R; Hutanu I; Deraco M
Eur J Cancer; 2013 Oct; 49(15):3140-8. PubMed ID: 23831335
[TBL] [Abstract][Full Text] [Related]
11. Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma.
Alexander HR; Bartlett DL; Pingpank JF; Libutti SK; Royal R; Hughes MS; Holtzman M; Hanna N; Turner K; Beresneva T; Zhu Y
Surgery; 2013 Jun; 153(6):779-86. PubMed ID: 23489943
[TBL] [Abstract][Full Text] [Related]
12. Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
Baratti D; Kusamura S; Cabras AD; Dileo P; Laterza B; Deraco M
Ann Surg Oncol; 2009 Feb; 16(2):463-72. PubMed ID: 19082859
[TBL] [Abstract][Full Text] [Related]
13. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion.
Deraco M; Nonaka D; Baratti D; Casali P; Rosai J; Younan R; Salvatore A; Cabras Ad AD; Kusamura S
Ann Surg Oncol; 2006 Feb; 13(2):229-37. PubMed ID: 16444562
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of continuous hyperthermic peritoneal perfusion for the prophylaxis and treatment of peritoneal metastasis of advanced gastric cancer: evaluation by multivariate regression analysis.
Hirose K; Katayama K; Iida A; Yamaguchi A; Nakagawara G; Umeda S; Kusaka Y
Oncology; 1999; 57(2):106-14. PubMed ID: 10461056
[TBL] [Abstract][Full Text] [Related]
15. Hyperthermo-chemotherapy combined with cytoreductive surgery for the treatment of gastric cancer with peritoneal dissemination.
Yonemura Y; Fujimura T; Fushida S; Takegawa S; Kamata T; Katayama K; Kosaka T; Yamaguchi A; Miwa K; Miyazaki I
World J Surg; 1991; 15(4):530-5; discussion 535-6. PubMed ID: 1891941
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of the peritoneal carcinomatosis by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy (IHPC): postoperative morbidity and mortality and short-term follow-up].
Minicozzi A; Borzellino G; Momo EN; Segattini C; Pitoni F; Steccanella F; De Manzoni G
Ann Ital Chir; 2008; 79(4):231-9. PubMed ID: 19093624
[TBL] [Abstract][Full Text] [Related]
17. [Continuous hyperthermic peritoneal perfusion (CHPP) for prevention or treatment of peritoneal dissemination].
Kusano H; Miyashita K; Matsuo T; Jibiki M; Nakagoe T; Miura T; Tomita M
Gan To Kagaku Ryoho; 1993 Aug; 20(11):1622-5. PubMed ID: 8373233
[TBL] [Abstract][Full Text] [Related]
18. Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study.
Brigand C; Monneuse O; Mohamed F; Sayag-Beaujard AC; Isaac S; Gilly FN; Glehen O
Ann Surg Oncol; 2006 Mar; 13(3):405-12. PubMed ID: 16485159
[TBL] [Abstract][Full Text] [Related]
19. Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study.
Tilleman TR; Richards WG; Zellos L; Johnson BE; Jaklitsch MT; Mueller J; Yeap BY; Mujoomdar AA; Ducko CT; Bueno R; Sugarbaker DJ
J Thorac Cardiovasc Surg; 2009 Aug; 138(2):405-11. PubMed ID: 19619785
[TBL] [Abstract][Full Text] [Related]
20. Toxicity and outcomes associated with surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with sarcomatosis.
Lim SJ; Cormier JN; Feig BW; Mansfield PF; Benjamin RS; Griffin JR; Chase JL; Pisters PW; Pollock RE; Hunt KK
Ann Surg Oncol; 2007 Aug; 14(8):2309-18. PubMed ID: 17541691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]